General AML

Selinexor monotherapy in R/R AML patients: a phase 1 study

Selinexor is a novel, Selective Inhibitor of Nuclear Export (SINE) compound, which inhibits Exportin 1 (XPO1), a karyopherin protein, that facilitate…

Cynthia Umukoro , Mar 29, 2017

General AML

The FDA grants annamycin Orphan Drug Designation for the treatment of AML

On 22nd March 2017, the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to annamycin  for the treatment of patients with…

Cynthia Umukoro , Mar 24, 2017

General AML

Iomab-B given ‘positive scientific advice’ by the EMA CHMP for the treatment of R/R AML

On 21st March 2017, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) gave Positive…

Cynthia Umukoro , Mar 23, 2017

General AML

Therapeutic strategy for AML patients with loss of ALDH1A1

Aldehyde Dehydrogenase 1A1 (ALDH1A1), an isoform of Aldehyde Dehydrogenase (ALDH), is highly expressed on Hematopoietic Stem Cells (HSCs) and it…

Cynthia Umukoro , Mar 17, 2017

General AML

Chemosensitization with plerixafor plus G-CSF in R/R AML - a phase 1/2 study

Acute Myeloid Leukemia (AML) blasts express the chemokine receptor CXCR4, which interacts with the bone marrow microenvironment and contributes to…

Cynthia Umukoro , Mar 17, 2017

General AML

The FDA halts clinical trials of selinexor in AML

The U.S. Food and Drug Administration has placed a partial hold on clinical trials of the experimental drug selinexor (KPT-330), a XPO1 antagonist,…

Cynthia Umukoro , Mar 14, 2017

General AML

The FDA grants FATE-NK100 Investigational New Drug Application clearance for treatment of R/R AML

On 13th March 2017, the U.S. Food and Drug Administration (FDA) granted Investigational New Drug (IND) application clearance for FATE-NK100, a…

Cynthia Umukoro , Mar 14, 2017

General AML

Outcomes of APL patients treated with ATRA-ATO and gemtuzumab

Previous reports on three consecutive prospective trials (ID01-014, NCT01409161, & NCT00413166) with All Trans Retinoic Acid (ATRA) in…

Cynthia Umukoro , Mar 13, 2017

General AML,   FLT3,   & 1 more

Clofarabine in newly diagnosed AML patients: HOVON-102 study

Clofarabine, a nucleoside analogue, has been shown to exhibit anti-leukemic activity in older patients with Acute Myeloid Leukemia (AML). However,…

Cynthia Umukoro , Mar 10, 2017

General AML

The FDA lifts clinical hold on the phase I trials of vadastuximab talirine in AML

On 6th March 2017, the U.S. Food and Drug Administration (FDA) lifted a clinical hold on the phase I clinical trials of experimental drug…

Cynthia Umukoro , Mar 8, 2017